Elutia (ELUT) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
23 Apr, 2026Voting matters and shareholder proposals
Election of two Class III directors, David Colpman and Kevin Rakin, is up for shareholder vote.
Ratification of PricewaterhouseCoopers LLP as independent auditor for 2026 is proposed.
Approval sought for the First Amendment to the Amended and Restated 2020 Incentive Award Plan.
Advisory vote on executive compensation ("say on pay") and on the frequency of future say-on-pay votes are included.
Board of directors and corporate governance
Board recommends voting for all director nominees and for all proposals presented.
Shareholders may withhold authority for individual nominees or vote for all.
Executive compensation and say-on-pay
Advisory, non-binding vote on executive compensation is included.
Shareholders to select preferred frequency (one, two, or three years) for future say-on-pay votes.
Latest events from Elutia
- Shareholders will vote on director elections, auditor ratification, and key compensation matters.ELUT
Proxy filing23 Apr 2026 - Q4 revenue up 16%, BioEnvelope sale drove debt repayment, and NXT-41x FDA process advanced.ELUT
Q4 202511 Mar 2026 - FDA clearance for EluPro and improved margins offset by a $28.2M net loss in Q2 2024.ELUT
Q2 20242 Feb 2026 - EluPro launches as a biologic alternative in the cardiac device protection market, with full rollout in 2025.ELUT
H.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026 - EluPro launches in January, poised to disrupt the $600M pacemaker market with superior technology.ELUT
17th Annual LD Micro Main Event Conference17 Jan 2026 - Q3 net income rose to $1.3M on SimpliDerm growth and EluPro adoption, but risks persist.ELUT
Q3 202414 Jan 2026 - Scaling EluPro adoption and advancing NXT-41X, with strong financial and market momentum.ELUT
Cantor Global Healthcare Conference 202531 Dec 2025 - EluPro's rapid adoption and Boston Scientific partnership fuel growth and improved margins.ELUT
Q4 202424 Dec 2025 - Offering up to $100M in securities, including $50M at-the-market stock, to fund growth amid losses.ELUT
Registration Filing16 Dec 2025